Therapeutic Oligonucleotides

Therapeutic Oligonucleotides.- Dinucleotides Containing 3¢-S-Phosphorothiolate Linkages.- 2’-O,4’-C-Methyleneoxymethylene Bridged Nucleic Acids (2’,4’-BNACOC).- A Non-covalent Peptide-based Strategy for Ex-vivo and In vivo Oligonucleotide Delivery.- Cell Penetrating Peptides-based Strategies for the Delivery of Splice Redirecting Antisense Oligonucleotides.- A Nanoparticle for Tumor Targeted Delivery of Oligomers.- Light-directed Delivery of Nucleic Acids.- Antibody Targeted siRNA Delivery.- Aptamer-Drug Conjugation for Targeted Tumor Cell Therapy.- Five-step Process for Screening Antisense Compounds for Efficacy: Gene Target IL-12Rb2.- Diverse Small Non-coding RNAs in RNA Interference Pathways.- Quantification of siRNAs In vitro and In vivo.- Optimization of Transfection Conditions and Analysis of siRNA Potency Using Real-time PCR.- siRNA Knockdown of Gene Expression in Endothelial Cells.- Using RNA Interference in Schistosoma mansoni.- Performing the Labeled microRNA Pull-down (LAMP) Assay System: An Experimental Approach for High-throughput Identification of microRNA-target mRNAs.- Synthesis, Purification, and Characterization of Oligoribonucleotides that Act as Agonists of TLR7 and/or TLR8.- Synthesis, Purification, and Characterization of Immune-Modulatory Oligodeoxynucleotides that Act as Agonists of Toll-like Receptor 9.- Surface Plasmon Resonance Investigation of RNA Aptamer-RNA Ligand Interactions.- Practical Considerations for Analyzing Antigene RNAs (agRNAs): RNA Immunoprecipitation of Argonaute Protein.- Inhibition of Human Papillomavirus Expression Using DNAzymes